Charles S. Kuzma

Hematology

220 Page Rd
Pinehurst, NC 28374

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.

Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 09, 2026

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 13, 2026

Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

Journal: International journal of radiation oncology, biology, physics

Published: December 11, 2025

Breadth and Depth of Patient and Caregiver Supportive Services in Community Oncology (WF-1803CD).

Breadth and Depth of Patient and Caregiver Supportive Services in Community Oncology (WF-1803CD).

Journal: Psycho-oncology

Published: July 16, 2024

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.

Journal: Blood

Published: July 24, 2023

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 09, 2023

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 19, 2022

Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.

Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 17, 2021

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.

Journal: Leukemia

Published: January 26, 2021

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.

Journal: Journal of thrombosis and haemostasis : JTH

Published: August 02, 2019

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Journal: The New England journal of medicine

Published: December 04, 2018

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 15, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026